Oncolytics Biotech (NASDAQ:ONCY) Rating Reiterated by HC Wainwright
Oncolytics Biotech (NASDAQ:ONCY – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 441.18% from the company’s current price. Oncolytics […]
More Stories
Insider Selling: The Williams Companies, Inc. (NYSE:WMB) CAO Sells 7,951 Shares of Stock
The Williams Companies, Inc. (NYSE:WMB – Get Free Report) CAO Mary A. Hausman sold 7,951 shares of the business’s stock...
Neurogene (NASDAQ:NGNE) Price Target Raised to $72.00 at Leerink Partners
Neurogene (NASDAQ:NGNE – Free Report) had its price target hoisted by Leerink Partners from $45.00 to $72.00 in a research...
EVgo Reports Record Third Quarter 2024 Results
EVgo Inc., a leading electric vehicle charging solutions provider, unveiled its financial results for the quarter ending September 30, 2024....
Buck Wealth Strategies LLC Decreases Position in Visa Inc. (NYSE:V)
Buck Wealth Strategies LLC lowered its position in shares of Visa Inc. (NYSE:V – Free Report) by 10.6% in the...
Empower Advisory Group LLC Lowers Stock Holdings in Uber Technologies, Inc. (NYSE:UBER)
Empower Advisory Group LLC lowered its holdings in Uber Technologies, Inc. (NYSE:UBER – Free Report) by 0.3% in the third...
Geneva Capital Management LLC Cuts Stake in Raymond James (NYSE:RJF)
Geneva Capital Management LLC decreased its holdings in Raymond James (NYSE:RJF – Free Report) by 3.5% in the 3rd quarter,...